Volume 22, Number 10—October 2016
Dispatch
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Table
Patient no. | Age, y/sex | Underlying condition | Intensive care | Days hospitalized | Chest radiograph† | 13-mo titer‡ |
34-mo titer‡ |
|||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ELISA | IFA | MN | ELISA | IFA | MN | |||||||
02 | 31/M | Atrial septal defect | Yes | 16 | Right lobar pneumonia | >6,400 | Pos | 160 | 1,600 | Pos | 80 | |
03§ | 60/M | Hypertension | NA | NA | Bilateral consolidation; pneumonia | 400 | Pos | 20 | <400 | Ind | 20 | |
04 | 35/M | Hypertension | Yes | 8 | Bilateral lobar pneumonia | >6,400 | Pos | 80 | 400 | Pos | 40 | |
06 | 46/M | None reported | No | 6 | Right bronchial congestion with bronchovascular markings | 1,600 | Pos | 20 | 1,600 | Pos | 20 | |
09 | 45/M | None reported | No | 10 | Left consolidation; right infiltrate | 400 | Pos | 40 | <400 | Neg | 40 | |
11¶ | 41/F | None reported | No | 4 | ND | 1,600 | Pos | <20 | 400 | Neg | <20 | |
HH303§ | 39/F | Pregnant | NA | NA | NA | 1,600 | Pos | 80 | 400 | Pos | 80 |
*IFA, immunofluorescence assay; Ind, indeterminate; MN, microneutralization assay; NA, not applicable; ND, not documented; neg, negative; pos, positive.
†Taken within 3 days of presentation.
‡Antibodies against Middle East respiratory syndrome coronavirus.
§Symptomatic but refused hospitalization.
¶Classified overall as being serologically negative at 34 mo.
Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.